Research - Great news for our suggested uniQure (QURE) position – Bristol-Myers Squibb (BMY) is putting up $100 million upfront to partner with the European gene therapy developer … Continue Reading
Premium: Read NowResearch - Trillium Therapeutics raised approximately $50 million in a secondary offering this week. The company is well-financed through 2016 and initial (critical) data on lead program, SIRPaFc. … Continue Reading
Premium: Read NowResearch - Our suggestion to take profits on some of our bigger winners late last week was well-timed. From the blow-off top (temporarily, at least) on Friday … Continue Reading
Read NowResearch - With biotech where it is, we're suggesting taking profits on a number of our big winners in the past 6 months. Here are the details on CEMP, BLUE, TRIL, SAGE, MRNS, SGYP, GBIM, QURE, and TKMR.
Read NowResearch - Synergy Pharmaceuticals (SGYP) will shortly report phase 3 data from two large trials of lead candidate plecanatide in Chronic Constipation.
Premium: Read NowResearch - SAGE Therapeutics (SAGE) and Marinus Pharmaceuticals (MRNS)are innovators in a class of molecules known as neurosteroids and both target epilepsy initially.
Premium: Read NowResearch - Conatus Pharmaceuticals' (CNAT) CMO, Dr. Gary Burgess, tendered his resignation on Thursday. Here's why investors should take note.
Premium: Read Now
